MarketCap
Facebook
X
Telegram
SpringWorks Therapeutics ROCE Ratio | SWTX
Annual ROCE Ratio SpringWorks Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -57.81 | -54.78 | -50.28 | -41.07 | -8.32 | -18.35 | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -8.32 | -57.81 | -38.43 |
Quarterly ROCE Ratio SpringWorks Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.8 | -35.5 | -56.77 | -64.25 | -71.5 | -54.95 | -66.67 | -66.58 | -64.54 | -49.21 | -57.98 | -55.73 | -40.11 | -23.8 | -27.67 | -22.47 | -15.89 | -10.33 | -15.72 | -16.61 | -17.66 | 42.37 | 81.05 | 112.81 | 166.48 | 286.87 | 27.0 | 49.06 | - | 177.52 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 286.87 | -71.5 | 1.88 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
TG Therapeutics
TGTX
|
13.56 | $ 64.27 | 1.4 % | $ 9.28 B |  USA |
 |
Aphria Inc.
APHA
|
-2.49 | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
-14.58 | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
-44.26 | - | -6.00 % | $ 238 M | USA |
 |
Trevi Therapeutics
TRVI
|
-26.85 | $ 14.92 | -2.55 % | $ 2.01 B | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
-51.86 | - | - | $ 376 M | USA |
 |
AzurRx BioPharma, Inc.
AZRX
|
1008280076442.74 | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
-165.76 | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
-30.35 | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
-29.73 | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
-21.36 | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
-8.19 | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
-6.64 | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
-76.77 | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
-100.1 | - | - | $ 256 M | Canada |
 |
argenx SE
ARGX
|
14.31 | $ 972.42 | 1.05 % | $ 59.6 B |  Niderland |
 |
XBiotech
XBIT
|
-39.68 | $ 1.97 | 3.2 % | $ 60.1 M | USA |
 |
Neos Therapeutics, Inc.
NEOS
|
-37.85 | - | -2.54 % | $ 57.2 M | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
-90.5 | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
-92.78 | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
0.55 | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
-17318.55 | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-38.33 | $ 1.76 | -2.09 % | $ 2.99 M | USA |
 |
Viridian Therapeutics
VRDN
|
-43.85 | $ 30.86 | 2.22 % | $ 3.14 B | USA |
 |
Translate Bio, Inc.
TBIO
|
-0.85 | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-22.0 | - | - | $ 1.94 B | Canada |
 |
Urovant Sciences Ltd.
UROV
|
-441.32 | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-15.64 | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
-40.18 | - | -4.97 % | $ 664 M | USA |
|
Yunhong International
ZGYH
|
-0.45 | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
-62.79 | - | -7.58 % | $ 264 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-63.09 | $ 41.4 | 2.35 % | $ 3.28 B | Canada |
 |
Leap Therapeutics
LPTX
|
-26.75 | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
-86.57 | $ 31.45 | 2.08 % | $ 1.62 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-147.82 | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
34.51 | $ 12.67 | -0.98 % | $ 3.02 B | USA |
 |
Cortexyme
CRTX
|
162.59 | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
9.48 | $ 3.66 | -1.35 % | $ 802 M | Britain |
 |
Daré Bioscience
DARE
|
-476.75 | $ 0.69 | 1.75 % | $ 7.71 M | USA |
 |
Fate Therapeutics
FATE
|
-71.29 | $ 1.78 | -8.51 % | $ 211 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-5505.94 | $ 16.05 | -2.85 % | $ 217 M | USA |
 |
Halozyme Therapeutics
HALO
|
19.97 | $ 103.0 | 0.08 % | $ 12.3 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
-2.75 | $ 15.34 | 0.1 % | $ 13.2 B | China |
 |
iBio
IBIO
|
-40.22 | $ 0.78 | -1.89 % | $ 81.2 M | USA |
 |
Kodiak Sciences
KOD
|
-148.93 | $ 108.01 | 0.85 % | $ 5.75 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
30.97 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M | Canada |